In a retrospective cohort study of 31 patients with recurrent HCC after liver transplantation, the combined use of mTOR inhibitor (everolimus or sirolimus) and sorafenib identified a median overall survival of 19.3 months after initiation of the combined treatment, with a median time to disease progression of 6.77 months [54]. This evidence concerns the gene MTOR and hepatocellular carcinoma.